Forte Biosciences (FBRX) Net Cash Flow Growth (3y) (2019 - 2026)
Powered by 
Analysis
Forte Biosciences (FBRX) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 52.78% |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | -16.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16.05% |
| Mar 31, 2026 | -53.32% |
| Dec 31, 2025 | -77.46% |
| Sep 30, 2025 | -62.80% |
| Jun 30, 2025 | 249.10% |
| Mar 31, 2025 | 139.59% |
| Dec 31, 2024 | 53.60% |
| Sep 30, 2024 | -16.61% |
| Jun 30, 2024 | -14.44% |
| Mar 31, 2024 | -18.62% |
| Dec 31, 2023 | -30.74% |
| Sep 30, 2023 | 75.43% |
| Jun 30, 2023 | -35.80% |
| Mar 31, 2023 | -36.17% |
| Dec 31, 2022 | -58.38% |
| Sep 30, 2022 | 42.12% |
| Jun 30, 2022 | -27.63% |
| Mar 31, 2022 | 41.07% |
| Dec 31, 2021 | -30.23% |
| Sep 30, 2021 | -65.53% |